# Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

> **NCT00380159** · PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)-1 Infection

## Interventions

- **DRUG:** Elvucitabine
- **DRUG:** Lamivudine
- **DRUG:** Emtricitabine

## Key facts

- **NCT ID:** NCT00380159
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-12
- **Final completion:** 2009-01
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2023-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00380159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00380159, "Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00380159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*